

ForPatients

by Roche

Hepatocellular Carcinoma (HCC)

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma

Trial Status

Active, not recruiting

Trial Runs In

2 Countries

Trial Identifier

NCT04712643 ML42612

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.

Hoffmann-La Roche

Sponsor

Phase 3

Phase

NCT04712643 ML42612

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No
